|Toxiciy Grade:||5||City/State/Province:||New York, NY|
|Treatments:||Chemotherapy, Radiation||Hospital:||Memorial Sloan-Kettering Cancer Center|
This phase 2 study involved 52 newly diagnosed primary central nervous system lymphoma patients. The median patient age was 60 years and 30 were male.
Patients were treated with a chemotherapy regimen of rituximab, methotrexate, procarbazine, vincristine, and cytarabine, and with radiation therapy.
There were three treatment-related deaths due to neutropenia with fever. Grade 4 gastrointestinal perforation and grade 3 kidney toxicity were also reported.
The median overall survival was 79.2 months.
This study was partially supported by Genentech.
Correspondence: Dr. Antonio Omuro; email: email@example.com